Navigation Links
Hoping to Ease Shortage, FDA Fast-Tracks Generic Form of Cancer Drug
Date:2/4/2013

MONDAY, Feb. 4 (HealthDay News) -- Seeking to ease potentially dangerous shortages of a key cancer drug, the U.S. Food and Drug Administration on Monday announced it had fast-tracked the approval of the first generic form of one such medication, Doxil (doxorubicin).

"The agency is committed to doing everything we can to address drug shortages so that patients can get the medicines they need when they need them," Capt. Valerie Jensen, director of the Drug Shortage Staff at the FDA's Center for Drug Evaluation and Research, said in an agency news release. "For the past year, the FDA has been working to ensure that supplies of [doxorubicin] were not interrupted."

The new generic version is made by Sun Pharma Global and will be available in 20 milligram and 50 milligram vials. Like brand-name Doxil, the injected drug is administered intravenously by a health care professional.

Generic drugs approved by the FDA have the same quality and strength as brand name drugs, and the generic manufacturing and packaging sites must pass the same quality standards as those of brand name drugs, the agency noted.

In response to the Doxil shortage, the FDA announced in February 2012 that it would allow temporary controlled importation of Lipodox, an alternative to Doxil that is produced by Sun Pharma Global but not approved in the United States.

The FDA also decided to allow the release of one lot of Janssen's Doxil made under an unapproved manufacturing process.

For the time being, the FDA said it will continue to allow the controlled importation of Lipodox. Once there is enough of Sun's generic version to meet projected demand, the FDA will halt imports of any unapproved doxorubicin product.

Shortages of potentially life-saving cancer medications have plagued the U.S. health care system for the past two years.

Speaking at the annual meeting of the American Society for Clinical Oncology last June, Dr. Richard Schilsky, chair of ASCO's government relations committee, told reporters that some shortages had eased, "but there is still an unpredictable availability of many drugs and we are never sure exactly when a generic drug is suddenly going to go out of supply."

According to Schilsky, "that creates a tremendous amount of uncertainty -- anxiety for our patients and great difficulty in planning if you're a physician."

In October of 2011, President Barack Obama signed a special Executive Order demanding action on the issue, which is often caused by interruptions in manufacturing as companies address safety issues.

Besides Doxil, other drugs that have seen interruptions in supply include nitrogen mustard (used to fight blood cancers), paclitaxel (important for breast cancer and other tumors), 5-FU (used in a variety of cancers), and methotrexate (important to treat certain lymphomas).

More information

The U.S. Food and Drug Administration has more about drug shortages.

-- Robert Preidt

SOURCES: Richard Schilsky, M.D., chairman, government relations committee, American Society of Clinical Oncology; U.S. Food and Drug Administration, news release, Feb. 4, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Generic HIV treatment strategy could save nearly $1 billion annually but may be less effective
2. 1/3 of Docs Often Prescribe Brand-Name Drugs Over Generics: Study
3. People May Skip Generic Pills if Color Differs From Brand-Name Drug
4. Differences in generic pill characteristics may lead to interruptions in essential medication use
5. Inconsistency Seen in Safety Labeling for Generic Drugs
6. Regenstrief study finds that generic drugs often have incorrect safety labeling
7. FDA Pulls One Generic Form of Wellbutrin Off the Market
8. Toward competitive generic drug prices in Canada
9. Generic drugs key to US overseas HIV relief
10. FDA Approves Generic Versions of Plavix
11. Plavixs New Generic Status Could Be Boon for Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hoping to Ease Shortage, FDA Fast-Tracks Generic Form of Cancer Drug
(Date:2/18/2017)... ... ... Park Cities Pet Sitter President, Joette White, has been featured on Episode ... The episode, which was posted this week, features a 30-minute interview of White by ... Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business of ...
(Date:2/17/2017)... ... February 17, 2017 , ... The ... systems change designed to further positively impact the health and wellness of our ... long considered it our duty to seriously consider releasing our assets beyond our ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — ... Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's 8th ... of clinical trial planning and management. Pharmica discussed the importance of effective project ... attendees stopping by Pharmica’s booth were able to demo its cloud-based Resource ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Research and Markets has announced the addition of ... to their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:2/17/2017)... AMSTERDAM , Feb. 17, ... connected health offerings at the  ...  (NYSE: PHG,AEX: PHIA), a global ... a broad range of population ... personal health solutions, fully integrated in a ...
(Date:2/16/2017)... 16, 2017 Research and Markets has ... Medical Device Technologies" report to their offering. ... Traditional medical ... general instruments, non-drug coated implantables, large endoscopes, needle based drug ... over the last two to three decades for the treatment ...
Breaking Medicine Technology: